Mochida Pharmaceutical Articles
News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals
26 November 2012
Mochida diabetes deal with Merck; Vanda links with Megapharm
14 December 2011
Lundbeck partner Mochida files for escitalopram approval in Japan
17 September 2010
Mochida profit growth steady in FY 2008
5 June 2009
Mochida seeks OTC switch for Epadel
9 February 2009
Wyeth licenses Mochida's portfolio of TRPV1 antagonists
21 January 2008
More NCEs added to Japan's NHI reimbursement list late December
14 January 2008
Nine NCEs added to Japan's NHI drug list
8 October 2007
Novartis and Mochida to co-promote Diovan
29 January 2007
Mochida to file two Japanese NDAs
13 February 2006
Lundbeck swaps Cipralex partner in Japan
10 June 2002
Ostex signs serum test deal with Mochida
11 March 2002
Ostex signs serum test deal with Mochida
11 March 2002
Mochida closing plant
9 June 1999
Mochida Pharma Appointments
7 January 1999
Mochida Faces Up To Hard Times
1 October 1998
Forecast Changes By Japan Company Handbook
6 November 1995
Japanese Invest In UK's Peptide Therapeutics
19 June 1995
Hismanal Approval
20 February 1995
TOKYO STOCK COMMENT
14 March 1994
TOKYO STOCK COMMENT
8 February 1993
MOCHIDA OBESITY TREATMENT
7 September 1992
Showing 1-25 of 25 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
